This project is Memorial Sloan-Kettering Cancer Center's (MSKCC) application to become a Network Lead Academic Participating Site for the NCI National Clinical Trials Network (NCTN). The MSKCC project aims are scientific leadership in development of NCTN trials, scientific leadership in the activities of the NCTN and NCI Scientific Steering Committees, patient accrual on NCTN Trials, and mentoring junior investigators in clinical trial research. MSKCC has the resources to both bring strong scientifically driven studies to the network and to participate in studies brought forth by other network participants. MSKCC has a multidisciplinary team of investigators committed to translational research, a large patient population amenable to participation in clinical trials, an superb infrastructure to support such trials. MSKCC has full membership in Alliance for Clinical Trials in Oncology, GOG and RTOG and is an affiliate member of ECOG. MSKCC has strong leadership and expertise in advanced imaging and participates in ACRIN studies on a case-by-case basis. The multiple Principal Investigators in this Network Lead Academic Site U10 are experienced leaders in the Network Groups with a track record of meeting these scientific, accrual and mentoring aims. As a large center focused solely on cancer, we have a particular expertise and commitment to the NCTN mission of evaluating rare tumors.

Public Health Relevance

As a Network Lead Academic Participating Site MSKCC will be a leader in the scientific development, conduct and accrual of NCTN clinical trials with the overall goal of developing new treatments for cancer patients. This will be achieved through definitive, randomized, clinical treatment and advanced imaging trials across a broad range of diseases and diverse patient populations, as well as development efforts preliminary to those trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA180791-03
Application #
9025758
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Mooney, Margaret M
Project Start
2014-04-15
Project End
2019-02-28
Budget Start
2016-03-01
Budget End
2017-02-28
Support Year
3
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Mandelblatt, Jeanne S; Cai, Ling; Luta, George et al. (2017) Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance). Breast Cancer Res Treat 164:107-117
Freedman, Rachel A; Foster, Jared C; Seisler, Drew K et al. (2017) Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527. J Clin Oncol 35:421-431
Venook, Alan P; Niedzwiecki, Donna; Lenz, Heinz-Josef et al. (2017) Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA 317:2392-2401
Giuliano, Armando E; Ballman, Karla V; McCall, Linda et al. (2017) Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA 318:918-926
Sanchez-Martin, Marta; Ambesi-Impiombato, Alberto; Qin, Yue et al. (2017) Synergistic antileukemic therapies in NOTCH1-induced T-ALL. Proc Natl Acad Sci U S A 114:2006-2011
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050
Holstein, Sarah A; Jung, Sin-Ho; Richardson, Paul G et al. (2017) Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol 4:e431-e442
Parsons, J Kellogg; Pierce, John P; Mohler, James et al. (2017) Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer. BJU Int :
Thaker, P H; Salani, R; Brady, W E et al. (2017) A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852). Ann Oncol 28:505-511
Vaz-Luis, Ines; O'Neill, Anne; Sepucha, Karen et al. (2017) Survival benefit needed to undergo chemotherapy: Patient and physician preferences. Cancer 123:2821-2828

Showing the most recent 10 out of 60 publications